OncoMatch/Clinical Trials/NCT06168487
Telmisartan in Prostate Cancer
Is NCT06168487 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies Telmisartan for prostate cancer.
Treatment: Telmisartan — The goal of this clinical trial is to learn about the tolerability of telmisartan in patients with prostate cancer, but evidence for treatment efficacy will also be gathered.
Check if I qualifyExtracted eligibility criteria
Cancer type
Prostate Cancer
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: standard of care agent for prostate cancer (cabazitaxel, docetaxel, abiraterone, olaparib, rucaparib, talazoparib plus enzalutamide) — receiving or likely to receive
Participants must be receiving or likely to receive one of the following SOC agents for PC: cabazitaxel, docetaxel (alone or plus abiraterone) olaparib, rucaparib, or talazoparib plus enzalutamide
Cannot have received: angiotensin I receptor blocker
Angiotensin l receptor blocker use currently or within the 30 days prior to day 1, cycle 1.
Cannot have received: (lithium)
Patients on lithium therapy in any form
Cannot have received: (rituximab)
Patients who received rituximab ... within 30 days prior to first telmisartan dose on this study
Cannot have received: (amifostine)
Patients who received ... amifostine within 30 days prior to first telmisartan dose on this study
Cannot have received: (ramapril)
Patients on ramapril
Lab requirements
Blood counts
hb >10 gm/dl
Kidney function
serum creatinine ≤2.5 or estimated gfr >30 cc/min
Liver function
scot ≤3x uln
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Dartmouth Health · Lebanon, New Hampshire
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify